Introduction
Epilepsy is a complex neurological disorder that affects approximately 1% of the population worldwide. Currently available conventional antiepileptic drugs (AEDs) provide control in only 75-80% of epileptic patients. 1 These agents mainly affect transport of ions across the cell membrane and/or modulate inhibitory or excitatory neurotransmission. 2 A wide array of adverse effects associated with these agents are a major limitation for their long term use. 3 Therefore, the development of a novel antiepileptic agent with better efficacy and minimal adverse effects would be an interesting prospect in the field of medical research. Calcium ions (Ca 2+ ) play an important role during epileptogenesis. It has been noticed that an increase in Ca 2+ influx in the cell triggers seizurogenic activity in the neurons. 4 Recently, Ca 2+ channel blockers, particularly dihydropyridines per se and with AEDs have been shown to decrease the incidence of seizures in various experimental models of epilepsy. 5, 6 Trimetazidine is a lipophilic piperazine derivative, a drug of interest in ischemic diseases. It has been found to improve symptoms and frequency of angina by maintaining Ca 2+ homeostasis in the cells. [7] [8] [9] In ischemic cardiomyopathy, trimetazidine has been found to prevent accumulation of calcium in cells by regulating exchange of ions across the membrane. 10 It has demonstrated anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties in various experimental animal models. 11 Several studies have demonstrated that it protects not only heart 8, 12 from ischemic injury but also brain, 13, 14 lung, 15 kidney, 16 intestine 17 and liver. 18 A potent neuroprotective activity of trimetazidine has been observed against stroke in the gerbil model of transient global ischemia. 14 In another study, trimetazidine was found to exhibit anti-excitotoxic activity in vestibular ganglionic neurons of rat. This anti-excitotoxic activity of trimetazidine was shown to be mediated via modulation of AMPA/kainate receptors. 19 Most of these studies have focused on anti-ischemic profile of trimetazidine while data on its possible neurological actions especially on epilepsy are essentially lacking. Thus, the objective of the present study was to explore the possible effects of trimetazidine on electroshock-induced seizure in mice.
Materials and methods

Animals
Swiss albino male mice weighing 24-35 g were used in the study. Animals were procured from the Central Animal House, University College of Medical Sciences, University of Delhi, Delhi. Animals were housed in groups of six mice per cage (43 cm Â 28.6 cm Â 15.5 cm) with a natural light/dark cycle and provided with free access to pellet diet and water. All the experiments were conducted between 9:30 a.m. and 6:30 p.m. in the neuropharmacology laboratory of the department. Procedures adopted during experiments on animals and their care were 
Drugs and dosing schedules
The following drugs were used: trimetazidine (Trivedon-20 mg tabs, Cipla Ltd., Mumbai, India), phenytoin (Sigma St Louis, MO, USA), and nimodipine (Nimodip 30 mg tabs, USV Ltd., Mumbai, India). Trimetazidine, phenytoin and nimodipine were suspended with 1% carboxy methyl cellulose (CMC) in double-distilled water and administered once orally. Trimetazidine was administered in doses of 5, 10 and 20 mg/kg while phenytoin was given in doses of 12.5 and 25 mg/kg. Nimodipine was administered in doses of 10, 20 and 40 mg/kg. Control groups were administered with 1% carboxy methyl cellulose. All drugs were administered in a volume of 10 ml/kg body weight and the animals were tested 1 h after drug administration. 20 and modified by Marwah et al. 21 was used to determine seizure-threshold current (STC) for each animal. It is a widely used test to screen the anti-and pro-convulsant activity of a novel compound. The potential of an agent to increase seizure-threshold current can be assessed in this test. It was used in the present study to ascertain the efficacy of trimetazidine alone and in combination with phenytoin, a standard antiepileptic drug, and nimodipine, a calcium channel blocker, against electro-convulsions in mice. Starting with a current of 2 mA, electroshock was delivered to each mouse via ear electrodes as a single train of pulses (20 Hz for 0.2 s) with linearly increasing intensity of 2 mA/2 s using an electro-convulsiometer (Techno, India). The current at which tonic hind limb extension (HLE) occurred was recorded as the seizurethreshold current. If no tonic HLE was observed by the current of 30 mA, electroshock was terminated and this cut-off current was used in the analysis.
Statistical analysis
The results were expressed as mean AE Standard Error of Mean (S.E.M.). Statistical analysis of the data was done using one-way analysis of variance (ANOVA) followed by post hoc Tukey's test. The pvalues less than 0.05 were considered significant.
Results
Effect of trimetazidine on increasing current electroshock seizures test in mice
Single dose administration of trimetazidine (10 and 20 mg/kg), phenytoin (25 mg/kg) and nimodipine (20 and 40 mg/kg) significantly raised the seizure-threshold current as compared to control group. However, no significant elevation in seizure-threshold current was observed with administration of lower doses of trimetazidine (5 mg/kg), nimodipine (10 mg/kg) and phenytoin (12.5 mg/kg) when compared with control.
The combined administration of trimetazidine and phenytoin in their sub-anticonvulsant doses, i.e. 5 and 12.5 mg/kg, respectively caused significant increase in seizure-threshold current as compared to control, trimetazidine 5 mg/kg and phenytoin 12.5 mg/kg groups. Similarly, co-administration of trimetazidine (5 mg/kg) and nimodipine (10 mg/kg) in their sub-anticonvulsant doses significantly raised the seizure-threshold current when compared to control, trimetazidine (5 mg/kg) and nimodipine (12.5 mg/kg) alone treated groups (Table 1 ).
Discussion
Trimetazidine is a well-tolerated drug, indicated for clinical use in several ischemia related diseases. 7, 8 Being lipophillic in nature it crosses the blood brain barrier. 8 Trimetazidine inhibits the initiation of glutathione production and improves thiol component level in neuronal cells therefore, has shown beneficial effects on anti-oxidant enzymes in brain. 22 Recently, it has demonstrated neuroprotective effect on crush injury of sciatic nerve in rats. 23 Additionally, it has shown protection against animal models of inflammation, nociception, gastric injury 11 and iron-induced epilepsy. 24 In epilepsy it has been noticed that calcium plays an important role in generating seizures. Extensive literature has highlighted that Ca 2+ is a primary mediator during epileptogenesis and status epilepticus-induced neurotoxicity. 4, 25 It is well documented that epileptic depolarization of neurons is effectively suppressed by Ca 2+ channel blocking agents. The Ca 2+ channel inhibition by dihydropyridines exhibited protection in experimental models of seizures. 6, 26 Several animal studies have reported that dihydropyridines by virtue of their brain penetrating property potentiate the protective efficacy of some antiepileptic drugs like phenytoin, carbamazepine, valproic acid etc. 5, 25, 27 Various clinical reports have revealed beneficial effects of certain calcium channel blocking agents, i.e. nimodipine, cinnarizine and flunarizine as add-on treatment in epileptic seizures. 28, 29 In the present study trimetazidine was tested in doses 5, 10 and 20 mg/kg against electrically induced seizure in the mice. The results demonstrated that in ICES test trimetazidine in doses of 10 and 20 mg/kg dose significantly increased the seizure-threshold current as compared to control group. Trimetazidine in a dose of 5 mg/kg did not elicit protection when given alone against electrically induced seizure. However, co-administration of trimetazidine in 5 mg/kg dose with sub-anticonvulsant dose of nimodipine 10 mg/kg, a Ca 2+ channel blocker significantly increased the seizure-threshold current as compared to control group. The protection demonstrated by trimetazidine in the present study is consistent with previous experimental reports where Ca 2+ channel blockers have shown protection against various convulsive models of epilepsy. 6, 27, 30 The additive effect obtained in the present study might be due to possible similar mechanism of action or due to interaction at blood brain barrier. Transport of various drugs at the blood brain barrier is mediated by many transporters. These drug efflux transporters thought to limit the drug distribution in brain parenchyma. Recently, it has been shown that adjuvant treatment with nimodipine restored the normal hippocampal concentration of phenytoin in phenytoin refractory epilepsy model in rats which is considered due to its Pgp inhibiting activity. 31 In the present study the additive effect obtained might be due to increased concentration of these drugs at target site due to decrease efflux. Furthermore, the additive effect obtained may be due to possible similar mechanism of action. Nimodipine by inhibiting calcium channel has shown antiepileptic activity in various experimental models. Trimetazidine has also shown calcium antagonistic action. In a voltage clamp study using ventricular myocytes of guinea pig trimetazidine blocked the calcium channel and decreased the peak amplitude of calcium current. 32 Furthermore, it decreased the calcium ion content in the cytoplasm of undifferentiated HL-60 cell, this inhibitory effect was considered due to blockade of Ca 2+ channel. 33 Many studies have demonstrated that conventional AEDs like phenytoin exert its anticonvulsant action partially due to interaction with voltage dependent calcium channels. 34, 35 Schumacher et al. 36 have observed that phenytoin altered the low voltage activated Ca 2+ channels in cultured hippocampus neurons, rodent thalamic neurons and neuroblastoma cells. It partially antagonized the L-type Ca 2+ current. In the present study the subanticonvulsant dose of trimetazidine was also co-administered with a sub-anticonvulsant dose of phenytoin. The combination has significantly increased the seizure-threshold current as compared to control group. These results are comparable with the effect obtained with trimetazidine when given alone in higher doses of 10 and 20 mg/kg. The findings of the present study suggest that trimetazidine possesses anticonvulsant activity against electroshock-induced seizure test in mice, possibly due to modulation of Ca 2+ channels.
However, our findings are preliminary and further chronic, biochemical and clinical studies are required to explore the exact mechanism of action of trimetazidine in epilepsy.
